7 Nov 2017 07:00
Consort Medical plc
7 November 2017
Notice of Results
Consort Medical plc ("Consort Medical", "Consort") (LSE: CSRT), a leading, global, single source pharma services drug and delivery device company, will announce its interim results for the six months ended 31 October 2017 on Tuesday, 5 December 2017.
ENDS
Enquiries:
Consort Medical | Tel: +44 1442 867 920 |
Jonathan Glenn - Chief Executive Officer
Paul Hayes - Chief Financial Officer
FTI Consulting | Tel: +44 20 3727 1000 |
Ben Atwell / Simon Conway
Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.
Our businesses
Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectable products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.
Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com.
We employ c.2,000 people globally of which c.1,400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.